Repository logo
 

JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients.

Accepted version
Peer-reviewed

Repository URI

https://www.repository.cam.ac.uk/handle/1810/286785

Repository DOI

https://doi.org/10.17863/CAM.34092

Files

Accepted version (172.28 KB)

Type

Article

Change log

Authors

Description

Keywords

Antineoplastic Agents, Humans, Janus Kinase 2, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Nitriles, Protein Kinase Inhibitors, Pyrazoles, Pyrimidines

Journal Title

Leuk Res

Conference Name

Journal ISSN

0145-2126
1873-5835

Volume Title

75

Publisher

Elsevier BV

Publisher DOI

https://doi.org/10.1016/j.leukres.2018.10.010

Rights

http://www.rioxx.net/licenses/all-rights-reserved
Sponsorship
Medical Research Council (MC_PC_12009)
Wellcome Trust (109967/Z/15/Z)

Collections

Cambridge University Research Outputs